| Name | Title | Contact Details |
|---|---|---|
Mary McLaren |
Chief Financial Officer | Profile |
Vision Globale Lt is a Montrí©al, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
AHC is a Gainesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Eye Surgeon Associates is a Bettendorf, IA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
eviCore healthcare offers proven, diversified medical benefit management solutions that help clients reduce costs while increasing quality of care for their members. The company provides these solutions to managed care organizations and risk-bearing provider organizations serving commercial, Medicare and Medicaid populations. Powered by a team of specialized medical professional resources, extensive evidence-based guidelines and advanced technologies, the company supports clients by ensuring the right evidence-based care is delivered at the right time to the right patient at the right site of care. Flexible medical benefit management solutions are offered in: Diagnostic Testing and Imaging; Cardiology; Comprehensive Musculoskeletal and Pain Management; Medical and Radiation Oncology; Sleep Services; Lab Management; and Post-Acute Care (including participating in the CMS Bundled Payments for Care Improvement Initiative). eviCore is proud to help over 80 million Americans receive higher quality, lower cost healthcare.
BERG is a Boston-based biopharma company focused on taking a bold “back to biology” approach to therapeutic discovery using its unique AI-based Interrogative Biology® platform. This platform combines patient biology and AI-based analytics to engage the differences between healthy and disease environments. The patient’s own biology drives the platform’s results and guides us in the discovery and development of drugs, diagnostics and healthcare applications. Our platform utilizes patient population health data to bring actionable Patient IntelligenceTM to precision medicine applications. For patients this means faster discovery and development of treatments, more effective precision treatments for individuals as well as a reduction in costs to our healthcare systems. BERG has a robust product portfolio in oncology, endocrinology and neurology with mature assets in oncology entering mid and late stage trials. BERG is committed to improving the lives of patients through precision medicine made possible by our innovative platforms.